Please login to the form below

Not currently logged in
Email:
Password:

Verona appoints chief financial officer

Richard Bungay brings experience from Chroma, Celltech and AstraZeneca

Verona Pharma Richard BungayVerona has named Richard Bungay as the company's chief financial officer to replace Danny Lowe.

Bungay joins the UK-based biotech initially on a part-time basis as it looks to develop its portfolio of investigational medicines for respiratory diseases.

His most recent position was as part-time CEO of fellow UK biotech Chroma Therapeutics, which focuses on the development of novel small molecules for inflammation and oncology, having previously served as the company's chief financial officer.

Prior to his time at Chroma, Bungay was director of corporate communications and strategic planning at Celltech and spent several years as finance director within the respiratory and inflammation therapy area at AstraZeneca.

Dr Jan-Anders Karlsson, CEO of Verona Pharma, said: "Richard's experience in financial management of innovative R&D-based businesses as well as his experience in investor relations will be invaluable to Verona Pharma as we move our key clinical programmes forward and grow the company.”

10th September 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

COVID-19 is redefining the value of ‘critical jobs’: An opportunity for social care?
...
How to keep your weight under control during lockdown
...
Brands stepping up to show solidarity during COVID-19
The brands that are stepping up to show solidarity during COVID-19 will be those that are remembered long after pandemic passes....

Infographics